Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
Public ClinicalTrials.gov record NCT03737643. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.
Study identification
- NCT ID
- NCT03737643
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,407 participants
Conditions and interventions
Conditions
Interventions
- Bevacizumab Drug
- Durvalumab Drug
- Olaparib Drug
- Placebo olaparib Drug
- Durvalumab placebo Drug
- Carboplatin+Paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 4, 2019 (Actual)
- Primary completion
- Mar 17, 2025 (Actual)
- Completion
- Dec 23, 2026 (Estimated)
- Last update posted
- Jul 7, 2026
2019 – 2026
United States locations
- U.S. sites
- 26
- U.S. states
- 15
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Foothill Ranch | California | 92610 | — |
| Research Site | Los Angeles | California | 90095 | — |
| Research Site | Orange | California | 92868-3298 | — |
| Research Site | San Francisco | California | 94158 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Augusta | Georgia | 30912 | — |
| Research Site | Hinsdale | Illinois | 60521 | — |
| Research Site | Indianapolis | Indiana | 46202 | — |
| Research Site | Towson | Maryland | 21204 | — |
| Research Site | Detroit | Michigan | 48202 | — |
| Research Site | Springfield | Missouri | 65807 | — |
| Research Site | Middletown | New Jersey | 07748 | — |
| Research Site | Montvale | New Jersey | 07645 | — |
| Research Site | Albany | New York | 12208 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | Uniondale | New York | 11553 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | Dayton | Ohio | 45429 | — |
| Research Site | Hilliard | Ohio | 43026 | — |
| Research Site | Tulsa | Oklahoma | 74134 | — |
| Research Site | Lancaster | Pennsylvania | 17601 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Philadelphia | Pennsylvania | 19107-5097 | — |
| Research Site | Pittsburgh | Pennsylvania | 15224 | — |
| Research Site | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 188 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03737643, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 7, 2026 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03737643 live on ClinicalTrials.gov.